The Cancer Letter Archives
The Cancer Letter was founded in 1973, two years after Congress passed the National Cancer Act of 1971. These archives represent the first 40 years of The Cancer Letter, which is published weekly.
TCL
Vol.
37
No.
28
July 15, 2011
- NCI Moves Ahead With Trials Database, Reporting Studies In Progress At Cancer Centers
- Guest Editorial By Gregory Reaman: Memories Of A Merger Past
- Chi Van Dang Named Director of University Of Pennsylvania Abramson Cancer Center
- Monica Bertagnolli Elected Chair Of The Alliance For Clinical Trials In Oncology
TCL
Vol.
37
No.
29
July 22, 2011
- A Year at NCI: Harold Varmus Reflects On Provocative Questions, The Duke Scandal, Financial Disaster And Grant Review
- Part One Of A Two-Part Interview With NCI Director Harold Varmus
- Also: NCCN Committee Reaffirms Clinical Guideline Covering Avastin for Breast Cancer Indication
- ODAC Votes For Accelerated Approval For Adcetris For Two Lymphoma Indications
- Richard Pazdur’s Comments to ODAC
- Department of Defense Offering $16 Million in Cancer Research Grants
CCL
Vol.
34
No.
7
July 29, 2011
- RTOG: Hormone Therapy Increases Survival When Combined With Radiation Therapy
- Zaltrap Shows Improvement in Survival In Stage IV Metastatic Colorectal Cancer
- Trial: Decitabine Improves Survival in Myeloid Leukemia
- Gleevec For KIT-positive Tumors Shows 92 Percent Overall Survival
- VEGF Levels Can Predict Tumor’s Resistance to Avastin
- More Patients Get Screened, Colorectal Death Rates Drop
- Revlimid Shows 91 Percent Response in Non-Hodgkin’s
- Revlimid Also Demonstrates Response in Mantle Cell
- FPD-R Regimen Well-Tolerated, With 63 Percent Complete Response
- Overall Cancer Mortality Rates Higher For Men Than Women
- New Model For Risk Assessment Includes Alcohol, Exercise, Weight
- Researchers Identify Five Genes Associated With Melanoma Risk
- Stereotactic Body Radiotherapy Could Improve Overall Survival
- CMS Issues Coverage Decision For Provenge in Prostate Cancer
- Clinical Trials Approved By NCI CTEP Last Month
- Approval Granted For New Formulation of Lupron Depot
CCL
Vol.
34
No.
8
August 26, 2011
- Trastuzumab Showed Improved Survival In Stage IV Breast Cancer with CNS Metastases
- Majority of Invasive Bladder Cancer Patients Do Not Receive Full Recommended Care
- Pertuzumab Delays Progression In HER2-Positive Breast Cancer
- Sentinel Lymph Node Excision Has No Impact on Survival
- Increased Breast Density Can Lead to Higher Risk
- Computer Interpretation Software Does Not Improve Detection
- Bone Marrow Transplant Survival Has Doubled In Young Patients
- Two Studies Demonstrate Molecule Blocking Cell Damage
- Interim Analysis Suggests Paclical Can Reduce Blood Levels
- Hormone Therapy Can Reduce Survival In Men With Heart Problems
- Zometa Can Reduce Risk Of Skeletal-Related Events
- Cell Phone Radiation Does Not Raise Child’s Risk of Tumors
- Clinical Trials Approved by NCI CTEP Last Month